Clinical Observation on the Safety and Efficacy of Cardonilmab in the Treatment of Second-line and Above Advanced Melanoma and Advanced Renal Cancer

NCT06670300 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER_GOV

Sponsor class

Conditions

Participants Who Had Received Second-line or Higher Advanced Melanoma and Advanced Renal Cancer

Interventions

DRUG: cardonilimab

Sponsor

YongZhang